amiodarone has been researched along with Body Weight in 36 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to analyse the effects of demographic factors, clinical factors, and genetic polymorphisms of related gene loci on warfarin bleeding-related complications in the Han population." | 8.12 | Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin. ( Chen, W; Fu, J; Jiang, S; Lv, M; Wu, T; Xia, X; Zhang, J, 2022) |
| "The effects of neferine, a bisbenzylisoquinline alkaloid extracted from the Chinese traditional medicine seed embryo of Nelumbo nucifera Gaertn, on amiodarone-induced pulmonary fibrosis in mice were evaluated." | 7.79 | Protective effects of neferine on amiodarone-induced pulmonary fibrosis in mice. ( Liu, JD; Niu, CH; Wang, JL; Wang, Y; Xiao, JH, 2013) |
| "We examined the effect of high- (AHD) and low-dose (ALD) amiodarone on survival, hemodynamics, and left ventricular remodeling in rats with experimental myocardial infarction (MI)." | 7.72 | Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and hemodynamics in rats with experimental myocardial infarction. ( Ertl, G; Gaudron, P; Hu, K, 2004) |
| " Coadministration of amiodarone, and, moreover, the presence of heart failure increase the C/D ratio, from 2." | 7.68 | Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone. ( Coumel, P; Denjoy, I; Leclercq, JF; Mentré, F, 1990) |
| " In the present multicentre study, we sought to develop and validate a model including genetic and non-genetic factors to predict the daily fluindione dose requirement in elderly patients in whom VKA dosing is challenging." | 5.40 | A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone. ( Andro, M; Berndt, C; Duverlie, C; Emmerich, J; Golmard, JL; Gouin-Thibault, I; Lacut, K; Le Gal, G; Loriot, MA; Mahé, I; Moreau, C; Pautas, E; Peyron, I; Siguret, V, 2014) |
| "The purpose of this study was to analyse the effects of demographic factors, clinical factors, and genetic polymorphisms of related gene loci on warfarin bleeding-related complications in the Han population." | 4.12 | Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin. ( Chen, W; Fu, J; Jiang, S; Lv, M; Wu, T; Xia, X; Zhang, J, 2022) |
| "The effects of neferine, a bisbenzylisoquinline alkaloid extracted from the Chinese traditional medicine seed embryo of Nelumbo nucifera Gaertn, on amiodarone-induced pulmonary fibrosis in mice were evaluated." | 3.79 | Protective effects of neferine on amiodarone-induced pulmonary fibrosis in mice. ( Liu, JD; Niu, CH; Wang, JL; Wang, Y; Xiao, JH, 2013) |
| "We examined the effect of high- (AHD) and low-dose (ALD) amiodarone on survival, hemodynamics, and left ventricular remodeling in rats with experimental myocardial infarction (MI)." | 3.72 | Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and hemodynamics in rats with experimental myocardial infarction. ( Ertl, G; Gaudron, P; Hu, K, 2004) |
| " Coadministration of amiodarone, and, moreover, the presence of heart failure increase the C/D ratio, from 2." | 3.68 | Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone. ( Coumel, P; Denjoy, I; Leclercq, JF; Mentré, F, 1990) |
| "Amiodarone is a potent and efficacious antiarrhythmic agent, yet associated with its use are life-threatening pulmonary fibrosis and hepatotoxicity." | 3.68 | Repeated amiodarone exposure in the rat: toxicity and effects on hepatic and extrahepatic monooxygenase activities. ( Brien, JF; Daniels, JM; Leeder, RG; Massey, TE, 1990) |
| "Rats were treated with amiodarone (20 mg/kg/day) up to 6 weeks and the neurotoxicity was assessed by determining changes in motor coordination, pain-threshold and rectal temperature every week during treatment." | 3.67 | Neurotoxicity in rats following subchronic amiodarone treatment. ( Fernando, JC; Ho, IK; Mehendale, HM; Rao, KS, 1986) |
| "Amiodarone is a first-line antiarrhythmic for life-threatening ventricular fibrillation or ventricular tachycardia in children, yet little is known about its pharmacokinetics (PK) in this population." | 1.48 | A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. ( Al-Uzri, A; Atz, AM; Cohen-Wolkowiez, M; Dallefeld, SH; Green, TP; Harper, B; Hornik, CP; Laughon, M; Lewandowski, A; Melloni, C; Mendley, SR; Mitchell, J; Sullivan, JE; Wu, H; Yogev, R, 2018) |
| " In the present multicentre study, we sought to develop and validate a model including genetic and non-genetic factors to predict the daily fluindione dose requirement in elderly patients in whom VKA dosing is challenging." | 1.40 | A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone. ( Andro, M; Berndt, C; Duverlie, C; Emmerich, J; Golmard, JL; Gouin-Thibault, I; Lacut, K; Le Gal, G; Loriot, MA; Mahé, I; Moreau, C; Pautas, E; Peyron, I; Siguret, V, 2014) |
| " In a first pharmacokinetic study, rats were simultaneously co-administered with a single-dose of C." | 1.39 | Investigating herb-drug interactions: the effect of Citrus aurantium fruit extract on the pharmacokinetics of amiodarone in rats. ( Alves, G; Falcão, A; Rodrigues, M, 2013) |
| " vesiculosus and amiodarone, which determined a considerable decrease on amiodarone bioavailability in rats." | 1.39 | Herb-drug interaction of Fucus vesiculosus extract and amiodarone in rats: a potential risk for reduced bioavailability of amiodarone in clinical practice. ( Abrantes, J; Alves, G; Falcão, A; Rodrigues, M, 2013) |
| "Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose." | 1.32 | Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. ( Hanniman, EA; McCarthy, TC; Pollak, PT; Sinal, CJ, 2004) |
| " In summary, 7 appears to be less toxic than amiodarone while maintaining its electrophysiologic properties consistent with antiarrhythmic activity." | 1.31 | Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. ( Carlsson, B; Li, YL; Malm, J; Mellin, C; Nilsson, S; Singh, BN; Temciuc, M, 2002) |
| "Treatment with amiodarone, a potent antiarrhythmic drug, is associated with a dose-dependent increase in plasma cholesterol resulting from a decreased number of liver low-density lipoprotein (LDL) receptors." | 1.30 | Tri-iodothyronine prevents the amiodarone-induced decrease in the expression of the liver low-density lipoprotein receptor gene. ( Bakker, O; Hudig, F; Wiersinga, WM, 1997) |
| "Amiodarone, 150 mg, was injected over 15 seconds intravenously into 9 patients, 52 +/- 9 years of age, weighing between 65 and 98 kg (mean = 81 +/- 15." | 1.30 | Amiodarone concentration in human myocardium after rapid intravenous administration. ( Agapitos, E; Alexopoulos, G; Anastasiou-Nana, MI; Karli, JN; Margari, ZJ; Nanas, JN; Patsi, EN; Stamatelopoulos, SF, 1999) |
| "Amiodarone (AM) is an effective antidysrhythmic agent, restricted in use by the development of adverse effects, including potentially fatal AM-induced pulmonary toxicity (AIPT)." | 1.29 | Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. ( Brien, JF; Leeder, RG; Mandin, CC; Massey, TE; Rafeiro, E, 1996) |
| "Treatment with amiodarone resulted in a decrease in maternal weight gain compared to pair-fed vehicle-treated controls, however, neonatal weight gain was not affected." | 1.28 | Effects of amiodarone administration during lactation in Fischer-344 rats. ( Hill, DA; Reasor, MJ, 1992) |
| "Amiodarone is a diiodinated benzofuran derivative that has some structural similarities to the thyroid hormones and contains two iodine atoms per molecule." | 1.28 | Amiodarone antagonizes the effects of T3 at the receptor level: an additional mechanism for its in vivo hypothyroid-like effects. ( Lambert, C; Paradis, P; Rouleau, J, 1991) |
| "Amiodarone treatment induced a marked increase in both T4 and rT3 and tended to decrease T3 serum levels." | 1.27 | Effect of amiodarone on myosin isoenzymic distribution in rat ventricular myocardium. ( Bouveret, P; Gagnol, JP; Jungbluth, L; Mercadier, JJ; Nahum, D; Nokin, P; Schwartz, K; Wisnewsky, C, 1987) |
| "Typical phospholipidosis-like light and electron microscopic alterations were seen in the lung, their severity related to the extent of biochemical changes induced by amiodarone." | 1.27 | Amiodarone induced phospholipidosis. Biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone. ( Bertani, T; Bizzi, A; Boeri, R; Cini, M; Latini, R; Marchi, S; Pesenti, A; Riva, E; Tavbani, E; Veneroni, E, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (25.00) | 18.7374 |
| 1990's | 13 (36.11) | 18.2507 |
| 2000's | 5 (13.89) | 29.6817 |
| 2010's | 8 (22.22) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Carlsson, B | 1 |
| Singh, BN | 1 |
| Temciuc, M | 1 |
| Nilsson, S | 1 |
| Li, YL | 1 |
| Mellin, C | 1 |
| Malm, J | 1 |
| Xia, X | 1 |
| Fu, J | 1 |
| Wu, T | 1 |
| Chen, W | 1 |
| Jiang, S | 1 |
| Lv, M | 1 |
| Zhang, J | 1 |
| Dallefeld, SH | 1 |
| Atz, AM | 1 |
| Yogev, R | 1 |
| Sullivan, JE | 1 |
| Al-Uzri, A | 1 |
| Mendley, SR | 1 |
| Laughon, M | 1 |
| Hornik, CP | 1 |
| Melloni, C | 1 |
| Harper, B | 1 |
| Lewandowski, A | 1 |
| Mitchell, J | 1 |
| Wu, H | 1 |
| Green, TP | 1 |
| Cohen-Wolkowiez, M | 1 |
| Niu, CH | 1 |
| Wang, Y | 1 |
| Liu, JD | 1 |
| Wang, JL | 1 |
| Xiao, JH | 1 |
| Rodrigues, M | 2 |
| Alves, G | 2 |
| Falcão, A | 2 |
| Moreau, C | 1 |
| Pautas, E | 1 |
| Duverlie, C | 1 |
| Berndt, C | 1 |
| Andro, M | 1 |
| Mahé, I | 1 |
| Emmerich, J | 1 |
| Lacut, K | 1 |
| Le Gal, G | 1 |
| Peyron, I | 1 |
| Gouin-Thibault, I | 1 |
| Golmard, JL | 1 |
| Loriot, MA | 1 |
| Siguret, V | 1 |
| Al-Shammari, B | 1 |
| Khalifa, M | 1 |
| Bakheet, SA | 1 |
| Yasser, M | 1 |
| Lifschytz, T | 1 |
| Zozulinsky, P | 1 |
| Eitan, R | 1 |
| Landshut, G | 1 |
| Ohayon, S | 1 |
| Lerer, B | 1 |
| Engelhorn, T | 1 |
| Schwarz, MA | 1 |
| Heusch, G | 1 |
| Doerfler, A | 1 |
| Schulz, R | 1 |
| Abrantes, J | 1 |
| McCarthy, TC | 1 |
| Pollak, PT | 1 |
| Hanniman, EA | 1 |
| Sinal, CJ | 1 |
| Hu, K | 1 |
| Gaudron, P | 1 |
| Ertl, G | 1 |
| Schindler, R | 1 |
| Fielenbach, T | 1 |
| Rave, G | 1 |
| Stoykov, I | 1 |
| van Beeren, HC | 1 |
| Moorman, AF | 1 |
| Christoffels, VM | 1 |
| Wiersinga, WM | 2 |
| Bakker, O | 2 |
| Germack, R | 1 |
| Adli, H | 1 |
| Vassy, R | 3 |
| Perret, GY | 1 |
| Leeder, RG | 2 |
| Rafeiro, E | 1 |
| Brien, JF | 2 |
| Mandin, CC | 1 |
| Massey, TE | 2 |
| Hudig, F | 1 |
| Anastasiou-Nana, MI | 1 |
| Nanas, JN | 1 |
| Alexopoulos, G | 1 |
| Karli, JN | 1 |
| Margari, ZJ | 1 |
| Agapitos, E | 1 |
| Patsi, EN | 1 |
| Stamatelopoulos, SF | 1 |
| Williams, EM | 1 |
| Salako, L | 1 |
| Wittig, JH | 1 |
| Hill, DA | 1 |
| Reasor, MJ | 1 |
| Lévy, S | 1 |
| Lauribe, P | 1 |
| Dolla, E | 1 |
| Kou, W | 1 |
| Kadish, A | 1 |
| Calkins, H | 1 |
| Pagannelli, F | 1 |
| Moyal, C | 1 |
| Bremondy, M | 1 |
| Schork, A | 1 |
| Yin, YL | 2 |
| Nicolas, P | 2 |
| Uzzan, B | 2 |
| Pussard, E | 1 |
| Berdeaux, A | 1 |
| Perret, G | 2 |
| Louchahi, M | 1 |
| Paradis, P | 1 |
| Lambert, C | 1 |
| Rouleau, J | 1 |
| De Sandro, V | 1 |
| Chevrier, M | 1 |
| Boddaert, A | 1 |
| Melcion, C | 1 |
| Cordier, A | 1 |
| Richert, L | 1 |
| Leclercq, JF | 1 |
| Denjoy, I | 1 |
| Mentré, F | 1 |
| Coumel, P | 1 |
| Daniels, JM | 1 |
| Pirovino, M | 1 |
| Honegger, U | 1 |
| Müller, O | 1 |
| Zysset, T | 1 |
| Küpfer, A | 1 |
| Tinel, M | 1 |
| Pessayre, D | 1 |
| Wilson, BD | 1 |
| Jaworski, AJ | 1 |
| Donner, ME | 1 |
| Lippmann, ML | 1 |
| Young, RA | 1 |
| Mehendale, HM | 2 |
| Bagchi, N | 1 |
| Brown, TR | 1 |
| Banerjee, SK | 1 |
| Latini, R | 2 |
| Bizzi, A | 2 |
| Cini, M | 2 |
| Veneroni, E | 2 |
| Marchi, S | 2 |
| Riva, E | 2 |
| Nokin, P | 1 |
| Mercadier, JJ | 1 |
| Nahum, D | 1 |
| Bouveret, P | 1 |
| Wisnewsky, C | 1 |
| Jungbluth, L | 1 |
| Gagnol, JP | 1 |
| Schwartz, K | 1 |
| Pesenti, A | 1 |
| Tavbani, E | 1 |
| Boeri, R | 1 |
| Bertani, T | 1 |
| Rao, KS | 1 |
| Fernando, JC | 1 |
| Ho, IK | 1 |
| Stäubli, M | 1 |
| Studer, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care[NCT01431326] | 3,520 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs[NCT04278404] | 5,000 participants (Anticipated) | Observational | 2020-03-05 | Recruiting | |||
| "Population Pharmacokinetics and Pharmacodynamics of Amiodarone in Children: PK-AMIO"[NCT03842020] | 57 participants (Actual) | Interventional | 2019-02-13 | Completed | |||
| Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients[NCT04539158] | 200 participants (Anticipated) | Interventional | 2020-08-07 | Recruiting | |||
| Double Sequence External Defibrillation: A Randomized Controlled Trial in Patients With Atrial Fibrillation Refractory to DC Cardioversion[NCT03827915] | 100 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for amiodarone and Body Weight
| Article | Year |
|---|---|
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
35 other studies available for amiodarone and Body Weight
| Article | Year |
|---|---|
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Body Weight; Brain; Cal | 2002 |
Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Apolipoproteins E; Asian People; Bo | 2022 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
Topics: Amiodarone; Bayes Theorem; Body Weight; Child, Preschool; Clinical Trials as Topic; Dose-Response Re | 2018 |
Protective effects of neferine on amiodarone-induced pulmonary fibrosis in mice.
Topics: Amiodarone; Animals; Benzylisoquinolines; Body Weight; Cell Count; Hydroxyproline; Interleukin-2 Rec | 2013 |
Investigating herb-drug interactions: the effect of Citrus aurantium fruit extract on the pharmacokinetics of amiodarone in rats.
Topics: Administration, Oral; Amiodarone; Animals; Area Under Curve; Body Weight; Citrus; Dose-Response Rela | 2013 |
A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Body Weight; Drug Dosage Calculations; Female; Gene-Environment | 2014 |
A Mechanistic Study on the Amiodarone-Induced Pulmonary Toxicity.
Topics: Adenosine Triphosphate; Amiodarone; Animals; Body Weight; Glutathione; Hydroxyproline; Leukocyte Cou | 2016 |
Effect of triiodothyronine on antidepressant screening tests in mice and on presynaptic 5-HT1A receptors: mediation by thyroid hormone α receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amiodarone; Animals; Antidepressive Agents; Body Weight; Dos | 2011 |
Reduction of cerebral infarct size by dronedarone.
Topics: Amiodarone; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Dronedarone; Heart Rate; I | 2011 |
Herb-drug interaction of Fucus vesiculosus extract and amiodarone in rats: a potential risk for reduced bioavailability of amiodarone in clinical practice.
Topics: Amiodarone; Animals; Area Under Curve; Body Weight; Drug Administration Schedule; Fucus; Herb-Drug I | 2013 |
Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Glucose; Blotting, Northern; Body Weight; Cell Li | 2004 |
Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and hemodynamics in rats with experimental myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Body Weight; Dose-Response Relationship, Drug; Female; | 2004 |
A comparative study on the effects of oral amiodarone and trimeprazine, two in vitro retinyl ester hydrolase inhibitors, on the metabolic availability of vitamin A in rats.
Topics: Absorption; Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; | 2005 |
Effect of amiodarone and dronedarone administration in rats on thyroid hormone-dependent gene expression in different cardiac components.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Body Weight; Dronedarone; Gene Expression Regulation; H | 2007 |
Triiodothyronine and amiodarone effects on beta 3-adrenoceptor density and lipolytic response to the beta 3-adrenergic agonist BRL 37344 in rat white adipocytes.
Topics: Adipocytes; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Amiodarone; Analysis of Variance; | 1996 |
Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Body Weight; Carmustine; Cell Survival; Cells, Cultured | 1996 |
Tri-iodothyronine prevents the amiodarone-induced decrease in the expression of the liver low-density lipoprotein receptor gene.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Body Weight; Cholesterol, LDL; Dose-Response Relationsh | 1997 |
Amiodarone concentration in human myocardium after rapid intravenous administration.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Body Weight; Cardiomyopathy, Dilated; Female; Fibro | 1999 |
The effect on atrial and ventricular intracellular potentials, and other pharmacological actions of L9146, a non-halogenated benzo(b)thiophene related to amiodarone.
Topics: Action Potentials; Amiodarone; Animals; Body Weight; Dogs; Female; Heart; Heart Conduction System; H | 1977 |
Effects of amiodarone administration during lactation in Fischer-344 rats.
Topics: Amiodarone; Animals; Animals, Newborn; Body Weight; Female; Lactation; Liver; Lung; Milk; Rats; Rats | 1992 |
Amiodarone: influence of the route of administration on thyroid status and cardiac beta-adrenoceptors in the rat.
Topics: Administration, Oral; Amiodarone; Animals; Body Weight; Injections, Subcutaneous; Iodide Peroxidase; | 1991 |
In vivo effects of macrolides on thyroid hormone serum levels and on hepatic type 1 5'-deiodinase in rat. A comparative study with amiodarone, phenobarbital and propranolol.
Topics: Amiodarone; Animals; Anti-Bacterial Agents; Body Weight; Iodide Peroxidase; Liver; Macrolides; Male; | 1991 |
Amiodarone antagonizes the effects of T3 at the receptor level: an additional mechanism for its in vivo hypothyroid-like effects.
Topics: Amiodarone; Animals; Body Weight; Hypothyroidism; Iodine Radioisotopes; Male; Myosins; Organ Size; P | 1991 |
Comparison of the effects of propylthiouracil, amiodarone, diphenylhydantoin, phenobarbital, and 3-methylcholanthrene on hepatic and renal T4 metabolism and thyroid gland function in rats.
Topics: Amiodarone; Animals; Body Weight; Cytochrome P-450 Enzyme System; Cytochromes b5; Glucuronosyltransf | 1991 |
Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Body Weight; Dose-Response Relationship, Drug; Drug I | 1990 |
Repeated amiodarone exposure in the rat: toxicity and effects on hepatic and extrahepatic monooxygenase activities.
Topics: Amiodarone; Animals; Biotransformation; Body Weight; Drug Administration Schedule; Fibrosis; Injecti | 1990 |
Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?
Topics: Amiodarone; Animals; Body Weight; Chromatography, Gas; Chromatography, High Pressure Liquid; Enzyme | 1990 |
Amiodarone-induced pulmonary toxicity in the rat.
Topics: Administration, Oral; Amiodarone; Animals; Body Weight; Bronchoalveolar Lavage Fluid; Cell Count; Lu | 1989 |
Effects of short-term and long-term administration of amiodarone on hepatobiliary function in male rats.
Topics: Amiodarone; Animals; Bile; Body Weight; Chemical and Drug Induced Liver Injury; Diet; Enzymes; Male; | 1989 |
Comparison of the effects of amiodarone and ipodate on the rat heart.
Topics: Amiodarone; Animals; Body Weight; Heart; Ipodate; Male; Organ Size; Rats; Rats, Inbred Strains; Thyr | 1989 |
Amiodarone and desethylamiodarone tissue uptake in rats chronically treated with amiodarone is non-linear with the dose.
Topics: Amiodarone; Animals; Body Weight; Eating; Kinetics; Lung; Male; Phospholipids; Rats; Rats, Inbred St | 1987 |
Effect of amiodarone on myosin isoenzymic distribution in rat ventricular myocardium.
Topics: Aging; Amiodarone; Animals; Body Weight; Heart; Isoenzymes; Male; Myocardium; Myosins; Rats; Rats, I | 1987 |
Amiodarone induced phospholipidosis. Biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone.
Topics: Amiodarone; Animals; Body Weight; Eating; Lipidoses; Lung; Lung Compliance; Male; Phospholipids; Pul | 1987 |
Neurotoxicity in rats following subchronic amiodarone treatment.
Topics: Amiodarone; Animals; Benzofurans; Body Temperature; Body Weight; Drinking Behavior; Feeding Behavior | 1986 |
The effects of amiodarone on the electrocardiogram of the guinea-pig are not explained by interaction with thyroid hormone metabolism alone.
Topics: Amiodarone; Animals; Benzofurans; Body Weight; Electrocardiography; Guinea Pigs; Heart Rate; Male; M | 1986 |